CVCE vs. BPCR, USG, EGT, WINV, PU12, CYS, GV2O, TV2H, GV1O, and TAN
Should you be buying CVC Income & Growth stock or one of its competitors? The main competitors of CVC Income & Growth include BioPharma Credit (BPCR), Ultimate Sports Group (USG), European Green Transition Plc O (EGT), Worsley Investors (WINV), Puma VCT 12 (PU12), Chrysalis VCT (CYS), Gresham House Renewable Energy VCT 2 (GV2O), Thames Ventures VCT 2 Healthcare Shs (TV2H), Gresham House Renewable Energy VCT 1 (GV1O), and Tanfield Group (TAN). These companies are all part of the "asset management" industry.
CVC Income & Growth vs. Its Competitors
CVC Income & Growth (LON:CVCE) and BioPharma Credit (LON:BPCR) are both small-cap financial services companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.
BioPharma Credit has higher revenue and earnings than CVC Income & Growth. CVC Income & Growth is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.
CVC Income & Growth pays an annual dividend of GBX 0.08 per share and has a dividend yield of 7.1%. BioPharma Credit pays an annual dividend of GBX 0.07 per share and has a dividend yield of 7.7%. CVC Income & Growth pays out 47.3% of its earnings in the form of a dividend. BioPharma Credit pays out 70.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.
2.9% of CVC Income & Growth shares are held by institutional investors. Comparatively, 21.4% of BioPharma Credit shares are held by institutional investors. 0.1% of CVC Income & Growth shares are held by company insiders. Comparatively, 0.1% of BioPharma Credit shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
In the previous week, CVC Income & Growth's average media sentiment score of 0.00 equaled BioPharma Credit'saverage media sentiment score.
BioPharma Credit has a net margin of 80.20% compared to CVC Income & Growth's net margin of 0.00%. BioPharma Credit's return on equity of 8.51% beat CVC Income & Growth's return on equity.
Summary
BioPharma Credit beats CVC Income & Growth on 8 of the 11 factors compared between the two stocks.
Get CVC Income & Growth News Delivered to You Automatically
Sign up to receive the latest news and ratings for CVCE and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CVC Income & Growth Competitors List
Related Companies and Tools
This page (LON:CVCE) was last updated on 9/15/2025 by MarketBeat.com Staff
Free CVCE Stock Alerts